Trials / Completed
CompletedNCT04671056
Drug Interaction Study of MGL-3196 With Pioglitazone
A Single Center, Open-Label, Drug Interaction Study of MGL-3196 With Pioglitazone and to Assess Food Effect in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Madrigal Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine whether the single-dose pharmacokinetics (AUC) of pioglitazone are affected by chronic dosing with MGL-3196 100 mg/day in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MGL-3196 | MGL-3196 100 mg tablet administered orally in the morning for 13 days |
| DRUG | Pioglitazone 15mg | Pioglitazone 15 mg tablet administered orally on 2 separate days, initially on one day alone and again after MGL-3196 has been dosed to steady-state |
Timeline
- Start date
- 2018-11-09
- Primary completion
- 2018-12-11
- Completion
- 2019-01-05
- First posted
- 2020-12-17
- Last updated
- 2020-12-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04671056. Inclusion in this directory is not an endorsement.